


This example is for a patient who has NCCN low/very low-risk disease. Active surveillance insights are only reported for those who have NCCN very low-, low-, and favorable intermediate-risk disease, abiraterone insights are only reported for those who have NCCN high- and very high-risk disease, and ST-ADT biomarker results are only reported for those who have NCCN intermediate-risk disease.



Name: John Doe
Date of Birth: 08/08/1964

ArteraAI Prostate Test Report

PATIENT DETAILS

PATIENT
Name: John Doe
Date of Birth: 08/08/1964
Condition: Prostate Cancer

PHYSICIAN
Name: Adam Smith, MD
Clinic Name: Artera Hospital

CLINICAL AND PATHOLOGY
Clinical Tumor Stage: T1c
Pre-biopsy PSA: 3.8 ng/mL
Gleason Score: 6 (3+3)
Patient Age at Order Date: 71
NCCN Risk: Low

ORDER
Order Date: 07/01/2023
Test Run Date: 07/04/2023
Artera ID: AM-4Y-VRD-005K
Accession Number: ART-25-XXXXX

PROGNOSTIC RISK

LOW
ArteraAI Prognostic Raw Score=0.13

10-YEAR RISK OF DISTANT METASTASIS
(With standard of care treatment)

>35%
HIGH

10%
INTERMEDIATE

3%
LOW

THIS PATIENT
1.8% RISK

95% CI: 1.3%-2.3%

10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY
(With standard of care treatment)

0.8%
95% CI: 0.6%-1.0%

ACTIVE SURVEILLANCE (AS) INSIGHTS


This patient's relative risk of adverse pathology at radical prostatectomy (RP) is in the **30th percentile** of a cohort of patients managed with AS who had RP.

Consider AS

Consider Definitive Therapy

0100

ArteraAI Low RiskArteraAI Int.-High Risk


Reviewed by Laboratory Director
Joshua B. Kish, MD

07/07/2025 12:00PM
Review Date and Time (EST)

The ArteraAI Prostate Test results are provided to support risk-based decisions within the recommended guidelines, taking into consideration all other patient factors.

[By signing this I am confirming adequate quality of the material received, image reviewed and presence of cancer, unless otherwise noted in this report.]

- A Prognostic Risk:** The ArteraAI prognostic risk group can explain how aggressive the patient's prostate cancer is. The 10-year risk of distant metastasis is reported as a continuous variable with low-, intermediate-, and high-risk categories.
- B Additional Prognostic Endpoints:** In addition to the 10-year risk of distant metastasis, 10-year risk of prostate cancer-specific mortality is also reported. This can help provide more information to support optimized decision-making.
- C Active Surveillance Insights:** For men with NCCN very low-, low-, and favorable intermediate-risk prostate cancer, comparing their risk of adverse pathology to that of other patients who were on active surveillance (AS) and underwent radical prostatectomy can help determine if AS is a suitable management option.

This example is for a patient who has NCCN low/very low-risk disease. Active surveillance insights are only reported for those who have NCCN very low-, low-, and favorable intermediate-risk disease, abiraterone insights are only reported for those who have NCCN high- and very high-risk disease, and ST-ADT biomarker results are only reported for those who have NCCN intermediate-risk disease.

ARTERA

Name: John Doe
Date of Birth: 08/08/1964

ArteraAI Prostate Test Report

SPECIMEN DETAILS

Date of Biopsy: 05/08/2022
Procedure: Biopsy

Specimen Site: Prostate
Specimen ID: 22-00129


Gross Description: Received and reviewed
[1] H&E slide(s) labeled [22-00128]

SUPPLEMENTAL INFORMATION

PROGNOSTIC RISK

Comparison of this patient to those in same NCCN risk group

THIS PATIENT
49th percentile



0 NCCN LOW/VERY LOW RISK 100

This patient has an estimated 10-year risk of metastasis that is **lower than 51%** of patients in the same NCCN very low/low risk group.

CASE COMMENTS

Comments from Clinical

This report was electronically signed by Dr. Joshua B. Kish on 07/07/2023 at 12:00PM.

Testing Laboratory: 6800 Southpoint Pkwy, Suite 950, Jacksonville, FL 32216 | CLIA ID: 10D2258449 | Laboratory Director: Joshua B. Kish, MD
© 2025, ARTERA Inc. | TEL: 650 239 7018 | FAX: 650 231 6899 | EMAIL: support@artera.ai

2 of 4

D Comparison With National Comprehensive Cancer Network (NCCN) Risk Group: There is variability among patients within NCCN risk groups. A visualization is provided to show how the risk of metastasis, based on the ArteraAI risk score, compares to other patients with NCCN low/very low-risk disease.